by Anna Pagotto | Jul 6, 2021 | Market access, NICE, Oncology
Insights Market access for immuno-oncology (I-O) therapies in the UK The rapid development of immuno-oncology (I-O) therapies has transformed the cancer treatment landscape, but health technology assessment (HTA) agencies can decide against covering or reimbursing...
